Lymphoma study pulled before it began: N-803 after CAR t never tested
NCT ID NCT07049432
First seen Nov 20, 2025 · Last updated Jun 16, 2026 · Updated 32 times
Summary
This study aimed to see if the drug N-803 is safe to give as maintenance therapy after CAR T-cell treatment for people with relapsed or refractory B-cell non-Hodgkin lymphoma. It was designed for adults who had already responded to CAR T therapy. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.